Company news

Marker Therapeutics, Inc. news in 2025

Marker Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 14, 2025

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

November 5, 2025

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

November 3, 2025

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

October 6, 2025

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

August 28, 2025

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

August 26, 2025

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

July 30, 2025

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

June 17, 2025

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 19, 2025

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference

April 1, 2025

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

March 31, 2025

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

February 25, 2025

Decks in 2025